LDXH.F Stock Overview
A contract research and development company, develops, manufactures, and commercializes rapid point-of-care (POC) diagnostic products for diagnosis and management of infectious diseases in the United States and Australia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Lumos Diagnostics Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.029 |
| 52 Week High | AU$0.095 |
| 52 Week Low | AU$0.014 |
| Beta | 0.63 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -49.83% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| LDXH.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 0.007% | -0.06% |
| 1Y | -49.8% | -1.4% | 20.5% |
Return vs Industry: LDXH.F underperformed the US Medical Equipment industry which returned -1.4% over the past year.
Return vs Market: LDXH.F underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| LDXH.F volatility | |
|---|---|
| LDXH.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: LDXH.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine LDXH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Doug Ward | lumosdiagnostics.com |
Lumos Diagnostics Holdings Limited, a contract research and development company, develops, manufactures, and commercializes rapid point-of-care (POC) diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. The company’s products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers.
Lumos Diagnostics Holdings Limited Fundamentals Summary
| LDXH.F fundamental statistics | |
|---|---|
| Market cap | US$10.25m |
| Earnings (TTM) | -US$8.82m |
| Revenue (TTM) | US$8.21m |
1.2x
P/S Ratio-1.2x
P/E RatioIs LDXH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LDXH.F income statement (TTM) | |
|---|---|
| Revenue | US$8.21m |
| Cost of Revenue | US$3.81m |
| Gross Profit | US$4.41m |
| Other Expenses | US$13.23m |
| Earnings | -US$8.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 53.64% |
| Net Profit Margin | -107.38% |
| Debt/Equity Ratio | 0% |
How did LDXH.F perform over the long term?
See historical performance and comparison